The complaint centers on the company’s submission of a Biologics License Application for Deramiocel, which allegedly relied on modified statistical analysis plans that lacked regulatory backing. Plaintiffs contend that these undisclosed changes rendered the firm's public statements materially misleading throughout the specified class period. Investors who suffered financial losses are now being scouted by the DJS Law Group to serve as lead plaintiffs in the proceedings.
Investors target Capricor Therapeutics in securities class action
A federal class action lawsuit alleges Capricor Therapeutics misled shareholders by altering clinical trial statistical protocols for its drug, Deramiocel, without prior FDA authorization. The litigation covers investors who purchased stock between December 17, 2025, and July 26, 2026, as the company faces claims of violating the Securities Exchange Act.
Those seeking to participate in the recovery effort must act before the September 28, 2026, deadline. While the DJS Law Group is organizing the action, shareholders are not required to be appointed as lead plaintiffs to receive a potential share of any eventual settlement. The firm, led by David J. Schwartz, specializes in corporate governance and securities litigation, representing institutional clients in complex recovery matters.
Comments (0)
No comments yet. Be the first!